Brief: Denali - Informed By Sanofi Phase 2 Himalaya Study Evaluating Sar443820/Dnl788 Didn't Meet Primary Endpoint
16/02/2024 14:30
Feb 16 (Reuters) - Denali Therapeutics Inc DNLI.O :
* INFORMED BY SANOFI PHASE 2 HIMALAYA STUDY EVALUATING
SAR443820/DNL788 IN PARTICIPANTS WITH AMYOTROPHIC LATERAL
SCLEROSIS DIDN'T MEET PRIMARY ENDPOINT
* SANOFI INTENDS TO PRESENT DETAILED EFFICACY AND SAFETY
RESULTS
OF THE ALS PHASE 2 HIMALAYA STUDY AT A FUTURE SCIENTIFIC FORUM
* SANOFI WILL CONTINUE TO CONDUCT THE K2 PHASE 2 STUDY OF
SAR443820/DNL788 IN PARTICIPANTS WITH MULTIPLE SCLEROSIS
Source text for Eikon: ID:n0001714899-24-000065
Further company coverage: DNLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers